# Phase II Pharmacokinetics Study of CAM2038

> **NCT02710526** · PHASE2 · COMPLETED · sponsor: **Braeburn Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Opioid Use Disorder
- Chronic Pain

## Interventions

- **DRUG:** CAM2038

## Key facts

- **NCT ID:** NCT02710526
- **Lead sponsor:** Braeburn Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-05-17
- **Final completion:** 2017-07-03
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710526, "Phase II Pharmacokinetics Study of CAM2038". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02710526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*